Biopharma

1,910 Companies

Access all companies

Find technology partners quickly.

Spotfolio tracks over one million companies in technology industries.

There are 1,910 companies in the field of Biopharma on spotfolio that produce or deliver products, that utilize or research technologies or that are otherwise engaged in topics such as Clinical, Drug, Pharmaceutical, Research, Patients, Therapeutic, Disease, Treatment .

Start-ups (317)

Early-stage companies (449)

Established companies (970)

The majority of these companies is located in the following countries.

United States (927)

United Kingdom (138)

China (125)

Canada (86)

Example Companies

Find companies in your area

Enteris BioPharma

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

- Pipeline - Ovarest - Tobrate - CDMO Service - Partnering - Early Drug Discovery - Life Cycle Management - About Us - Executive Leadership -

- Pipeline - Ovarest - Tobrate - CDMO Service - Partnering - Early Drug Discovery - Life Cycle Management - About Us - Executive Leadership -

Oral Leuprolide Tablet for Treatment of Endometriosis and follow-on indications Tobrate™ Oral Tobramycin Tablet for Treatment of uUTI Octreotide Phase

scores vs. placebo after 12-week treatment period (p=0.018) Oral KORSUVA 1 mg was well-tolerated after 12 weeks of treatment Boonton, NJ – December 6, 2019

Peptelligence®-Engineered Oral CR845 (CR845/difelikefalin) in Chronic Liver Disease Patients BOONTON, NJ – March 1, 2018 – Enteris BioPharma, Inc., a biotechnology

Peptelligence®-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients Trial to evaluate pharmacokinetics and safety of three tablet

manufacturing expertise, Enteris BioPharma has an extensive history of documented clinical and partner success. Convenient & Scalable Our inspected and fully cGMP

News - Articles - Events - Resources - Careers Oral KORSUVA™ in Phase 2 Clinical Trial for Atopic Dermatitis Enteris BioPharma’s “Feasibility-to-Licensing”

Peptelligence®, to develop an oral formulation of a peptide-based injectable therapeutic from Ferring. Under the terms of the agreement, Enteris will conduct ...

program.” About Ferring Pharmaceuticals Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around

the past 10 years, there has been a rapid growth in the development of therapeutic proteins, with a significant increase in the number of protein-based drugs

September 21-24, 2020. During the conference, Enteris will be meeting with pharmaceutical executives to explore opportunities involving Peptelligence®, the company’s

Enteris BioPharma formulation team works in close collaboration with our pharmaceutical and biotech partners to develop highly optimized and bespoke Peptelligence

Johnson Pharmaceutical R&D, where he held leadership positions in Clinical Research and Regulatory Affairs, and as Medical Director of Ob/Gyn/Infertility at

Enteris Biopharma - Technologies - Peptelligence - ProPerma - Pipeline - Ovarest - Tobrate - CDMO Service - Partnering - Early Drug Discovery

Enteris Biopharma - Technologies - Peptelligence - ProPerma - Pipeline - Ovarest - Tobrate - CDMO Service - Partnering - Early Drug Discovery

Soricimed Soricimed Biopharma Inc.

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Action - 4. Intellectual Property - Oncology Programs - SOR-C13 - Peptide-Drug Conjugate - About - Our Team - For Investors - News and Events - Resources

Action - 4. Intellectual Property - Oncology Programs - SOR-C13 - Peptide-Drug Conjugate - About - Our Team - For Investors - News and Events - Resources

Development Program A first-in-class drug candidate in development for the treatment of solid-tumor cancer SOR-C13, is a novel, short, synthetic peptide developed ...

of treatment, 55% of patients had stable disease. One patient that came into the study with progressive disease was stable for more than one year. Promising

Analysis Group Partner to Validate Predictive Imaging Markers for SOR-C13 Treatment Response in Solid Cancer Tumors TORONTO, CANADA and LONDON, UNITED KINGDOM

Potential activity was demonstrated with 54% of subjects achieving stable disease TORONTO, Canada, February 23, 2016 – Soricimed Biopharma Inc. ("Soricimed")

Phase 1b Clinical trial of SOR-C13 TORONTO, CANADA / ACCESSWIRE / SEPTEMBER 24, 2019 – Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical

Soricimed Announces Clinical Advisory Board TORONTO, CANADA--(Marketwired - July 6, 2016) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical

diagnostics, is presenting a poster entitled SOR-C13, a novel cancer peptide therapeutic targeting the TRPV6 oncochannel shows efficacy in breast and ovarian cancer

2018-10-31 11:55:00 Soricimed Publishes New Research Validating TRPV6 as a Therapeutic Target for Ovarian Cancer MONCTON, New Brunswick, Oct. 31, 2018 (GLOBE

19, 2018 – Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing targeted cancer therapeutics, is

companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest

Resources - Contact 2016-04-16 02:00:00 AACR (American Academy for Cancer Research), New Orleans, Louisiana This conference theme, "Delivering Cures Through

of Soricimed, speaks on proof-of-concept study results at annual cancer research workshop. Jack Stewart, Chairman and Chief Scientific Officer of Soricimed

Canada MONCTON, NB, CANADA / ACCESSWIRE / SEPTEMBER 29, 2020 – Soricimed Biopharma Inc. ("Soricimed" or “the Company”), a clinical-stage company developing

News and Events - Resources - Contact 2013-05-23 16:07:00 Soricimed Biopharma Inc. Announces U.S. Trial Site for Phase I Clinical Trial of New Cancer

Cue Biopharma Cue Biopharma, Inc.

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Overview - Current Openings Careers Principal Scientist/Associate Director, Drug Substance CMC and External Manufacturing The Company Cue Biopharma, Inc

a patient’s body. Immuno-Oncology CUE-100 Series - MHC Class I / IL-2 Drug Discovery Optimization IND-Enabling Phase I Development Partner CUE-101 (HPV-E7 ...

Publications - Pipeline - Overview - Immuno-Oncology - Infectious Disease - Autoimmune Disease - Clinical Trials - CUE-101-01 HPV16+ HEAD AND NECK CANCER

protein for selective targeting and expansion of anti-tumor T cells for treatment of HPV-driven malignancies Saso Cemerski1, Steven N. Quayle1, Dharma Raj

protein for selective targeting and expansion of anti-tumor T cells for treatment of HPV-driven malignancies Steven N. Quayle1, Dharma Raj Thapa1, Sandrine

Publications - Pipeline - Overview - Immuno-Oncology - Infectious Disease - Autoimmune Disease - Clinical Trials - CUE-101-01 HPV16+ HEAD AND NECK CANCER

Overview - Leadership - Founders - Board of Directors - Scientific and Clinical Advisory Board - Our Approach - Overview - Scientific Presentations

Overview - Leadership - Founders - Board of Directors - Scientific and Clinical Advisory Board - Our Approach - Overview - Scientific Presentations

addressed regarding efficacy and patient safety. To that end, a superior therapeutic strategy would selectively and specifically modulate disease-relevant

immuno-oncology, and/or autoimmunity, with broad experience developing therapeutic approaches using in vivo models. Preferred experience assessing immunologic

Cue Biopharma, he held roles of increasing responsibility at Janssen Pharmaceutical Companies, including a key leadership position overseeing strategic

served as Chief Commercial Officer at Takeda Pharmaceuticals, a global pharmaceutical company, and, from 2010 to 2011, he served as Executive Vice President

Institute of Technology and a member of the Whitehead Institute for Biomedical Research. Dr. Ploegh is recognized for his contributions to molecular immunology

with co-founders Ron Seidel III, Ph.D., Executive Vice President, Head of Research and Development and Rudy Chaparro, Senior Advisor, pioneered the work that

Directors Charters Cue Biopharma Audit Committee Charter Cue Biopharma Code of Business Conduct and Ethics Cue Biopharma Compensation Committee Charter

Partnering - Careers - Overview - Current Openings Privacy Cue Biopharma respects the privacy of visitors to its website and is committed to the

Haihe Biopharma Shanghai HaiHe Pharmaceutical Co.,Ltd.

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

compounds with brand-new mechanisms to expand HaiHe’s innovative anti-tumor drug pipeline. By activating the body’s adaptive immune response, STING activator ...

(innovative anti-tumor drug), Huperzine-A (innovative drug against Alzheimer’s Disease), Depsides salts (a modern Chinese Medicine) and antofloxacin hydrochloride

investigator meeting on the phase III clinical trial of ON101, an innovative drug for the treatment of diabetic foot ulcer jointly developed by the two companies ...

“Microbio”) announced that the interim investigator meeting on the phase III clinical trial of ON101, an innovative drug for the treatment of diabetic foot ulcer

kinase in the MAPK signaling pathway. Targeting ERK can be used for the treatment of a variety of tumors caused by the prevalent mutations in the MAPK signaling

Phase II clinical trial of simmitecan LP-201 by HaiHe Biopharma in the treatment of neuroendocrine carcinoma July 19, 2019, Shanghai, China -HaiHe Biopharma

drugs is 3DMed’s important change aiming at the future trend of the chronic disease treatment of tumor. This move will help 3DMed to form a highly synergistic

Board - CEO Introduction - Management Team - Preclinical Pipelines - Clinical Product Introduction - Business Development - Business Media Contact

Asia-Pacific, which involving in oncology, diabetes, CV, CNS, and etc therapeutic areas. - QQ X

team, which involving in oncology, CV, nephropathy, endocrine, and etc. therapeutic areas. She has solid professional knowledge and skills, as well as excellent

HaiHe Biopharma Production Center Settles down in Taizhou Pharmaceutical High-Tech Zone | The Signing Ceremony Held Successfully Author: HaiHe Biopharma

has 3 years of oncology clinician and 20 years of experience in the pharmaceutical industry and management. She has been engaged in medical and research

pharma, diagnostic industry and cancer research institute. He worked as a senior scientist and vice president of research and development in Sanofi, Massachusetts

pharma, diagnostic industry and cancer research institute. He worked as a senior scientist and vice president of research and development in Sanofi, Massachusetts

Partnerships - Contact - CN|中文 logo More banner More - News Haihe Biopharma and 3DMed Reached Collaboration for Innovative Analgesics Haihe Pharmaceutical

Careers - Partnerships - Contact - CN|中文 logo More banner More Haihe Biopharma and 3DMed Reached Collaboration for Innovative Analgesics Haihe Pharmaceutical

Denovo Biopharma

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Pipeline News Careers Publications Contact Us 中文 Pipeline DB102: Anti-tumor Drug Enzastaurin Lilly conducted many clinical studies with enzastaurin in a

development of innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DB102 (enzastaurin) ...

serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need for such a disease or condition. Despite numerous

Biomarker-Guided Phase 2b Clinical Trial with DB102 (Enzastaurin) In First-Line Treatment of Glioblastoma (GBM) SAN DIEGO, Oct 15th, 2019 -- Denovo Biopharma LLC

Improved Survival with Enzastaurin Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients with the Novel Genetic Biomarker, DGM1 2018 ASH Abstract ...

Pharma BV: Research Funding; AstraZeneca: Membership on a Board or Advisory Committee; Denovo Biopharma LLC: Research Funding; Genentech: Research Funding;

Biopharma Receives Global Rights to a Novel Late-Stage Drug for Alzheimer’s Disease from Orion Corporation for Development as a Personalized Medicine SAN DIEGO

DIRECTOR/SENIOR DIRECTOR, CLINICAL DEVELOPMENT COMPANY DESCRIPTION Denovo Biopharma LLC, a clinical-stage biotechnology company that employs novel and

Director/Senior Director, Clinical Development Position Summary Reporting to the Head of Clinical Development, the Director/Senior Director, Clinical Development is

range of data sources to discover novel clinical biomarkers to improve therapeutic outcomes in complex diseases of unmet medical need with specific focus

range of data sources to discover novel clinical biomarkers to improve therapeutic outcomes in complex diseases of unmet medical need with specific focus ...

include individuals looking to bridge the gap between academic and industrial research environments to impact delivery of truly innovative and life-changing therapies

D. - Chief Business Officer Dr. Haller has broad experience in the pharmaceutical and biotechnology industries, with leadership roles in business development

compliance guidance to cross-functional teams including Chemical Development, Pharmaceutical Development, Analytical Development, Quality Control, and Clinical Supply

enzastaurin 2020/04 Denovo Biopharma To Acquire Tocagen’s Entire Replicating Gene Therapy Platform and Related Assets 2020/03 Denovo Biopharma Announces Breakthrough

information: info@denovobiopharma.com Privacy Policy Warning Regarding Denovo Biopharma Employee Impersonation Fraud Recently, we have received an increasing

Use detailed technology terms.

Only spotfolio allows for searching with detailed technology terms, as we provide you with all topics that technology companies talk about.

Use Cases

Register now

Why Technology Scouting?

Technology scouting is the basis for your innovation management, identifies new technological developments as early as possible and protects you from disruptive business models.

Identify technology partners

Boost your market research

Look beyond major players

Build long and short lists

Collect technology leaders, providers, start ups and potential new partners in lists via simple tagging to take further steps with your team.